Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Peg-Intron [peginterferon alfa-2b] as Maintenance Therapy vs. an Untreated Control Group in Adult Subjects With Compensated Cirrhosis (METAVIR F4), Secondary to Chronic Hepatitis C, Who Have Failed to Respond to Therapy With Any Alpha Interferon Plus Ribavirin.

Next Previous
Trial Profile

Peg-Intron [peginterferon alfa-2b] as Maintenance Therapy vs. an Untreated Control Group in Adult Subjects With Compensated Cirrhosis (METAVIR F4), Secondary to Chronic Hepatitis C, Who Have Failed to Respond to Therapy With Any Alpha Interferon Plus Ribavirin.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 06 May 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Peginterferon alfa-2b (Primary)
  • Indications Hepatitis C
  • Focus Registrational; Therapeutic Use
  • Sponsors Merck Sharp & Dohme; Schering-Plough

Most Recent Events

  • 07 Jul 2009 Actual patient number changed from 626 to 631 as reported by ClinicalTrials.gov.
  • 16 Jun 2009 Actual patient number (626) added as reported by ClinicalTrials.gov.
  • 28 May 2008 Status changed from in progress to completed, as reported on clinicaltrials.gov

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top